Viridian Therapeutics, Inc. develops medicines for autoimmune and rare diseases, focusing on differentiated investigational therapeutic candidates. The company utilizes expertise in antibody discovery and engineering to create a pipeline targeting high unmet medical needs. Its drug development strategy includes programs like thyroid eye disease, aiming to enhance existing treatment options with improved safety, tolerability, and patient convenience. Viridian operates primarily in the biopharmaceutical sector, targeting patients with specific medical conditions.
- Website
- www.viridiantherapeutics.com
- Issuer profile
- All listings